Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Six more countries add Prevenar to their immunisation programmes

This article was originally published in Scrip

Executive Summary

Wyethhas praised six countries for including its seven-valent pneumococcal conjugate vaccine, Prevenar, in their immunisation programmes. Cyprus, Bahrain, Hungary, Ireland, Slovakia and Sweden have become the latest countries to announce that they will routinely immunise infants against pneumococcal disease using Prevenar. This brings the total number of countries to include the vaccine in their programmes to 24, according to Wyeth. The company also points to Germany for proof of the vaccine's worth. "Since the introduction of PCV7 into Germany's paediatric immunisation schedule in 2006, there has been a 50% reduction in vaccine-type invasive pneumococcal disease in children younger than two years old compared with a pre-vaccine base-line", the company says. Pneumococcal disease leads to 1.6 million deaths a year across the world.

You may also be interested in...

Canada Counters Drug Shortages With Export Bans

Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.

The COVID-19 Economic Crisis – Fallout And Opportunities

In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts